Inactive Instrument

PREDILIFE Stock Euronext Paris

ALPRE

FR0010169920

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets
-	-

29/06	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
10/02	Intégrance Launches Preventive Health Program for Employees

News in other languages: PREDILIFE

17/07	Predilife : Bilan semestriel au 30/06/2026 du contrat de liquidité PREDILIFE
03/07	Predilife : RÉSILIATION DU CONTRAT DE LIQUIDITÉ CONCLU AVEC TSAF
02/07	Predilife : RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE
30/06	Un trimestre boursier exubérant, mais pas irrationnel ?
30/06	Predilife : PREDILIFE POINT CONCERNANT LA FDA ET MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

More news

Managers and Directors: PREDILIFE

Manager	Title	Age	Since
Stéphane Ragusa CEO	Chief Executive Officer	56	01/01/2004
Émilien Gauthier CTO	Chief Tech/Sci/R&D Officer	-	01/01/2007
Marion Renelier LAW	General Counsel	-	01/01/2016

Director	Title	Age	Since
Stéphane Ragusa CHM	Chairman	56	01/01/2004
Charles Vilgrain BRD	Director/Board Member	46	01/01/2018
Antoine Bricard BRD	Director/Board Member	58	01/01/2018

More insiders

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	4.14M 4.73M 4.73M 3.85M 3.53M 6.66M 456M 6.76M 45.82M 17.94M 223M 17.75M 17.37M 771M	P/E 2024	-3.18x	P/E 2025	-3.01x
Enterprise Value	8.92M 10.18M 10.18M 8.28M 7.61M 14.34M 982M 14.55M 98.66M 38.62M 481M 38.22M 37.4M 1.66B	EV / Sales 2024	34.5x	EV / Sales 2025	19.3x
Free-Float	48.75%	Yield 2024 *	-	Yield 2025	-

29/06	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
10/02	Intégrance Launches Preventive Health Program for Employees
10/10/25	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/07/25	Predilife S.A. announced a financing transaction	CI
06/06/25	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/04/25	Edil San Felice Bags EUR16 Million Maintenance Works Contract in Italy	MT
24/04/24	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/09/23	Predilife: a project accredited by Finance Innovation
15/07/23	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/04/23	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
12/04/23	Predilife: predictive assessment contract with Colas
29/10/22	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
25/04/22	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	CI

25/10/25	PREDILIFE : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025	PU
10/10/25	PREDILIFE : RESULTATS SEMESTRIELS 2025	PU
30/05/24	Predilife : PREDILIFE STRENGTHENS ITS ASSETS WITH THE ISSUANCE OF A PATENT FOR ITS AI METHOD	AT
01/05/24	Predilife : IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF EUR 25.07 REPRESENTS +391% POTENTIAL UPSIDE	AT
26/04/24	Predilife : Valuation of MammoRisk(R) software	AT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT SCIENCES CORPORATION	+0.95%	-.--%	+116.94%	+10.40%	20.03B
VERACYTE, INC.	-2.55%	+2.45%	+151.89%	+102.97%	4.75B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-2.79%	+2.43%	+112.90%	+171.66%	3.61B
IOVANCE BIOTHERAPEUTICS, INC.	-5.66%	+31.55%	+107.63%	-32.59%	2.45B
BGI GENOMICS CO., LTD.	+2.01%	+3.82%	-26.08%	-35.34%	2.08B
CAREDX, INC.	-1.97%	+30.59%	+196.31%	+255.41%	1.99B
MARAVAI LIFESCIENCES HOLDINGS, INC.	0.00%	+9.06%	+198.32%	-43.20%	1.05B
SEEGENE, INC.	-1.10%	-2.71%	-13.50%	+25.12%	837M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-0.14%	+1.86%	-36.72%	-14.16%	495M
Average	-1.25%	+8.34%	+89.74%	+48.92%	4.14B
Weighted average by Cap.	-0.48%	+5.43%	+113.96%	+44.02%

	2024	2025
Net sales	493K 563K 563K 458K 421K 793K 54.32M 804K 5.45M 2.13M 26.58M 2.11M 2.07M 91.81M	836K 954K 954K 776K 713K 1.34M 92.05M 1.36M 9.24M 3.62M 45.04M 3.58M 3.5M 156M
Net income	-4.26M -4.87M -4.87M -3.96M -3.64M -6.86M -470M -6.96M -47.17M -18.46M -230M -18.27M -17.88M -794M	-3.93M -4.49M -4.49M -3.65M -3.36M -6.32M -433M -6.42M -43.51M -17.03M -212M -16.86M -16.49M -732M
Net Debt	3.54M 4.04M 4.04M 3.28M 3.02M 5.69M 390M 5.77M 39.13M 15.32M 191M 15.16M 14.83M 659M	4.78M 5.45M 5.45M 4.44M 4.08M 7.68M 526M 7.79M 52.84M 20.68M 257M 20.47M 20.03M 889M

PREDILIFE Stock Euronext Paris

Stocks

ALPRE

FR0010169920

Biotechnology & Medical Research

Valuation: PREDILIFE

Latest news : PREDILIFE

Press Releases: PREDILIFE

News in other languages: PREDILIFE

Managers and Directors: PREDILIFE

Bio Diagnostics & Testing

Financials

Company Profile